Introduction {#s001}
============

P[rogress in reproductive techniques]{.smallcaps} and gene transfer methods nowadays allows targeted modifications of the porcine genome, although the overall success rates are still low.^[@B1]^ A bottleneck for porcine transgenesis is the lack of authentic embryonic stem (ES) cells, which are suitable for blastocyst complementation experiments.^[@B5],[@B6]^ Recently, the first attempts to generate porcine induced pluripotent stem (iPS) cells have been published^[@B7]^; however, the potential of current porcine iPS cells to contribute to chimera formation in blastocyst complentations,^[@B11]^ or to become reprogrammed by somatic cell nuclear transfer (SCNT),^[@B12]^ seems to be limited. Despite these bottlenecks, the recent employment of active transgenesis techniques based on ectopic enzymes, such as transposases, recombinases, and programmable nucleases, allows the generation of pig models at unprecedented pace.^[@B4]^

Nowadays, at least 90% of genetically modified pigs are generated for biomedical studies. Sequencing and annotation of the pig genome are important milestones to accelerate the generation of transgenic models. Since physiology, anatomy, pathology, genome organization, body weight, and life span of pigs and minipigs are more similar to those of humans, the domesticated pig represents an alternative biomedical model to rodents for specific human diseases.^[@B3],[@B6]^ This article briefly discusses the current progress of transgenic pig models for cancer, cardiovascular diseases, diabetes, neurodegenerative diseases, ophthalmology, and xenotransplantation ([Fig. 1](#f1){ref-type="fig"}), and future potential of this large animal model. Excellent comprehensive reviews regarding transgenesis in pigs in general and recent developments of innovative molecular tools, such as transposons, recombinases, and programmable nucleases, can be found elsewhere.^[@B3],[@B4],[@B13],[@B14]^

![Transgenic pigs as models for human diseases. **(A)** Rodent models differ in a number of critical parameters, such as size, life span, genome organization, physiology, and metabolism, from humans. **(B)** The domesticated pig and its minipig varieties seem to be relevant models for specific human diseases.](fig-1){#f1}

Porcine Biomedical Models {#s002}
=========================

Cystic fibrosis {#s003}
---------------

Cystic fibrosis (CF) is an autosomal recessive genetic disorder caused by mutations in the gene encoding the cystic fibrosis transmembrane conductance regulator (CFTR) that lead to pancreatic insufficiency, inadequate hydration of mucous secretion, and development of intestinal, hepatic, and lung disease.^[@B15],[@B16]^ The most prevalent cystic fibrosis mutation is a deletion of the phenylalanine at amino acid position 508 (Δ508).^[@B17]^

The efforts to develop a CFTR mouse model have not resulted in the appearance of the CF symptoms in this species.^[@B18]^ Importantly, genetically modified minipigs carrying either ΔF508, or CFTR knockout genotypes develop highly similar disease phenotypes as human patients ([Table 1](#T1){ref-type="table"}).^[@B19]^ This includes meconium ileus, defective chloride transport, early focal biliary cirrhosis, and pancreatic destruction.^[@B19]^

###### 

[Selected Pig and Minipig Models for Biomedical Research]{.smallcaps}

  *Model*                      *Comment*                                                               *Reference*
  ---------------------------- ----------------------------------------------------------------------- ----------------------------
  Xenotransplantation          Knockout of N-glycolylneuraminic acid and alpha-galactosyltransferase   Kwon et al.^[@B94]^
                               Expression of tumor necrosis factor ligand                              Klose et al.^[@B95]^
                               Expression of human leukocyte antigen                                   Weiss et al.^[@B96]^
                               *PERV* knockdown                                                        Dieckhoff et al.^[@B79]^
                               Expression of human *A20* (anti-apoptotic gene)                         Oropeza et al.^[@B97]^
  Cystic fibrosis              Knockout of cystic fibrosis transmembrane conductance receptor          Rogers et al.^[@B19]^
                               Expression of mutated CFTR protein                                      Ostedgaard et al.^[@B21]^
                               Intestinal CFTR expression in CF pigs                                   Stoltz et al.^[@B98]^
  Diabetes model               Expression of mutated hepatocyte nuclear factor-1                       Umeyama et al.^[@B39]^
                               Expression of mutated insulin 2                                         Renner et al.^[@B41]^
  Immunology                   Knockout of light chain                                                 Ramsoondar et al.^[@B99]^
                               Knockout of joining gene cluster                                        Mendicino et al.^[@B100]^
                               Knockout of interleukin-2 receptor subunit gamma                        Watanabe et al.^[@B64]^
                               Knockout of *RAG1/2*                                                    Huang et al.^[@B65]^
                               Expression of hCD46/HLA-E and knockout *GGTA1*                          Bongoni et al.^[@B74]^
  Neurodegenerative diseases   Expression of mutated huntingtin with polyglutamine tract               Yang et al.^[@B49]^
                               Expression of mutated human amyloid precursor protein                   Kragh et al.^[@B44]^
                               Expression of PSEN1M146I                                                Jakobsen et al.^[@B46]^
                               Expression of HTT protein (124Q) with human HD promoter                 Baxa et al.^[@B50]^
  Cancer                       Knockout of *BRCA1* gene                                                Luo et al.^[@B26]^
                               Expression of mutated *p53*                                             Sieren et al.^[@B25]^
                               Expression of mutated *APC*                                             Flisikowska et al.^[@B23]^
  Ophthalmology                Introduced deletion in *ELOVL4* gene                                    Sommer et al.^[@B60]^
                               Expression of mutated rhodopsin gene                                    Scott et al.^[@B56]^
  Cardiovascular diseases      Expression of mutated proprotein convertase subtilisin/kexin type 9     Al-Mashhadi et al.^[@B29]^

PERV, porcine endogenous retrovirus; CFTR, cystic fibrosis transmembrane conductance regulator; *GGTA1,* galactosyl transferase1 gene; HTT, huntingtin protein; HD, Huntington\'s disease; *BRCA1*, breast cancer 1 gene; *APC*, adenomatous polyposis coli; *ELOVL4,* elongation of very long chain fatty acids protein 4.

Porcine cancer models {#s004}
---------------------

Cancer is a group of more than 100 diseases caused by uncontrolled growth of cells. Different types of cancer are driven by genetic instability or epigenetic alterations of DNA repair genes, such as mutations in tumor suppressor genes and oncogenes. Although genetically engineered mouse models have significantly contributed to cancer biology,^[@B22]^ they still have significant limitations in their usefulness for modeling human cancer due to the differences of biology of human and mice.^[@B23]^

The first transgenic pig model for the Li Fraumeni syndrome was created by gene targeting of the tumor suppressor gene *TP53* in mesenchymal stem cells (MSCs) and subsequently using these cells in somatic cell nuclear transfer (SCNT).^[@B24]^ A latent R167H mutation in the *p53* orthologous gene of the human oncogene mutant R175H was created with conditional gene activation system by the Cre-lox recombinase system. The strategy used by Leuchs et al.^[@B24]^ resulted in 10-fold greater *p53-R167H* expression in homozygous MSCs similar to the expression status of the mutant human allele. However, no viable pigs were obtained with the homozygous mutation. Fifteen heterozygous piglets are currently observed for signs of tumor formation.

Recently, a successful porcine model for the development of Li Fraumeni syndrome has been generated and resulted in homozygous pigs expressing TP53-R167H. Lymphomas and osteogenic tumor formations were observed and confirmed by histopathological evaluation, computed tomography, and magnetic resonance imaging.^[@B25]^

Adenomatous polyposis coli (*APC*) is a tumor suppressor gene, and mutations may result in colorectal cancer such as familial adenomatous polyposis (FAP). Mutated genes from human patients generally contain premature stop codons between amino acids 1061--1309. Similar to FAP patients, the *APC* pigs exhibit dysplastic adenomas and abnormal crypt foci,^[@B23]^ making them a useful model for longitudinal studies of disease progression, development of early diagnosis, and potential interventions.

A breast cancer 1 gene (*BRCA1*) knockout model for mammary carcinogenesis in porcine has been developed by targeting exon 12 using adeno-associated virus (AAV)--mediated gene targeting and SCNT.^[@B26]^ The protein product of the *BRCA1* participates in DNA repair and checkpoint control processes.^[@B27]^ Since the homology between human and pig BRCA1 proteins (74%) is higher than the homology between human and murine proteins (58%), it is anticipated that cancer pathology and response to potentials drugs can be investigated by using this porcine model. Although heterozygous *BRCA1* knockout pigs were produced successfully, development of tumorigenesis was not observed because of the early mortality of the piglets.^[@B26]^

Cardiovascular diseases {#s005}
-----------------------

The domestic pig has been recognized as an excellent model for the human cardiovascular system due to similarities in coronary anatomy, physiology of heart, and blood flow.^[@B28],[@B29]^ Transgenic studies with relevance to cardiovascular diseases have been developed in pig models. Employing the *Sleeping Beauty* (*SB*) transposon system, minipigs with liver-specific expression of a mutant human proprotein convertase subtilisin/kexin type 9 (*PCSK9*) gene were generated.^[@B29]^ The transgenic pigs displayed reduced hepatic low-density lipoprotein (LDL) receptor levels, impaired LDL clearance, hypercholesterolemia, and spontaneous development of progressive atherosclerotic lesions.^[@B29]^

Promising results were obtained in transgenic pigs that carry a fatty acid desaturase (*FAD2*) gene from spinach (*Spinacia oleracea*) under the control of an adipocyte P2 promoter to increase linoleic acid level.^[@B30]^ Transgenic Yucatan pigs that express higher levels of endothelial nitric oxide synthase (eNOS) which regulates vascular function and structure by generating nitric oxide (NO) have been generated to investigate the regulation of vasodilation.^[@B31]^ Since vascular homeostasis by NO signaling is closely related to hydrogen peroxide (H~2~O~2~), which modulates the eNOS activity,^[@B32]^ the role of endothelium-derived H~2~O~2~ on cardiovascular disease has been investigated by the generation of transgenic minipigs that overexpress the human endothelial catalase.^[@B14],[@B33]^

Peroxisome proliferator-activated receptor-γ (PPAR-γ) has been seen as a target for therapeutic invention of cardiovascular disease due to its role on fatty acid uptake by adipocytes.^[@B34]^ Effects of PPAR-γ have been investigated with a new strategy for the production of transgenic pig models using zinc-finger nuclease technology following SCNT.^[@B35]^ These pig models promise to be useful in understanding of the human cardiovascular diseases and may serve as a model for testing new therapeutic strategies.

Diabetes {#s006}
--------

Diabetes mellitus (DM) is a group of metabolic disorders resulting from deficiency or ineffectiveness of endogenous insulin, which leads to an increase in blood glucose levels. Long-term hyperglycemia results in life-threatening consequences with dysfunction and failure of kidneys, heart, nerves, and blood vessels.^[@B36]^ Type I DM is also called juvenile diabetes, which is characterized by low production of insulin, while type II DM results from the resistance to insulin.

A transgenic pig model for type II DM was produced based on impaired glucose-dependent insulinotropic polypeptide (GIP) receptor using lentiviral transgenesis.^[@B37]^ The role of GIP in DM was demonstrated by a transgenic pig model, which showed significantly reduced oral glucose tolerance.^[@B38]^ Significant reduction in number and mass of β-cells were obtained in these transgenic pigs.^[@B37]^

A transgenic pig model expressing a dominant-negative hepatocyte nuclear factor 1α (*HNF-1α*), responsible for progressive reduction in insulin secretion was produced.^[@B39],[@B40]^ Although 12 of the 22 live born piglets died before weaning, 4 lived up to 196 days. Surviving piglets exhibited nonfasting blood glucose levels over 200 mg/dl. Diabetic characteristics include immature renal development and abnormal Langerhans islet formation in which high glucose level and poor insulin secretion were detected by histochemical analysis.^[@B40]^ More recently, a transgenic pig model for permanent neonatal diabetes, which has been associated with mutations in the insulin gene (*INS*) in humans,^[@B41]^ was generated by the introduction of an orthologous mutation in the pig genome.^[@B42]^ The transgenic pigs showed hyperglycemia soon after birth. A decrease in body weight (41%) and β-cell mass (72%) was observed at the age of 4.5 months. The production of *INS*^C94Y^ transgenic pigs having a stable diabetic phenotype might become an attractive model for insulin treatment studies.

Neurodegenerative diseases {#s007}
--------------------------

Alzheimer\'s disease (AD) is the most common multifactorial neural disorder characterized by progressive loss of memory and neurodegeneration in specific brain regions such as pyramidal cells in the cortex.^[@B42]^ Causative mutations have been identified in presenilin genes 1 and 2 (*PSEN1*, *PSEN2*), tau gene, and the amyloid precursor protein (*APP*) gene leading to increased production of hyper-phosphorylated tau in tangles and amyloid β-peptide (Aβ) in plaques, which in turn results in synaptic damage and neuropathy.^[@B43]^ A genetically modified pig model for AD was produced with a cDNA construct containing the Swedish mutation of human APP gene (*APPsw*).^[@B44]^ Although transgene expression was detected in brain tissues, Aβ peptide accumulation at symptomatic levels and appearance of a clinical consequences were yet not observed. At 1--2 years of age, the *APPsw*-carrying AD minipigs were analyzed by the spontaneous object recognition test (SORT) as a measure of memory. However, no significant differences were found in age-matched controls.^[@B45]^ It is estimated that AD symptoms may develop with increasing age of the animals.^[@B44]^

Recently, another AD pig model carrying *PSEN1M146I* mutation was developed. Therefore, a recombinase-mediated cassette exchange (RMCE) for targeted transgenesis and SCNT were employed.^[@B46]^ Up to now, no AD-like behavioral symptoms have been observed in these animals; however, onset of symptoms may take more time. Potentially, these models may offer the possibility for developing early diagnosis of AD.

Huntington\'s disease (HD) is an autosomal dominant, progressive neurodegenerative disorder characterized by expansion of a tri-nucleotide (CAG) repeat in the huntingtin gene (*HTT*) that results in extended amino-terminal poly-glutamine tracts ranging from 36 to 120 repeats. The mutated huntingtin protein misfolds, leading to aggregate accumulation in neurons that affects the transmission of neurotransmitters and are suspected to induce apoptosis.^[@B47],[@B48]^ Transgenic HD minipigs that express amino-terminal mutant *HTT* (105Q) under the control of the cytomegalovirus enhancer and chicken β-actin promoter were successfully generated via SCNT. The authors suggested that high levels of mutant *HTT* expression lead to early death phenotype of the carrier animals. Out of one litter, three of the five piglets died within 3 days and the fourth died at the age of 25 days. The fifth and vital piglet showed the lowest expression level of mutant HTT.^[@B49]^ Whereas genetic mouse models often failed to replicate overt neurodegeneration and apoptosis, histological analyses of brains sections from these piglets showed clear signs of apoptotic neurons with activated caspase-3 and DNA fragmentation.^[@B49]^

Baxa et al.^[@B50]^ recently reported the successful generation of transgenic HD minipigs using a lentiviral-based vector carrying human amino-terminal truncated *HTT* gene containing 145 repeats of CAG/CAA codons under the control of human *HTT* promoter. Although stable HTT expression was obtained in brain tissues, no motor deficits developed in this pig model so far.

Ophthalmology {#s008}
-------------

Retinitis pigmentosa (RP) is an inherited retinal disease that causes loss of central vision due to loss of light-sensitive photoreceptor neurons. Numerous mutations in various genes and loci can result in RP in humans, but the majority of autosomal dominant forms of RP cases are related to mutations in the rhodopsin (*RHO*) gene. Unlike laboratory rodents or dogs, swine is an appropriate choice as an RP model, since it has morphological and functional similarities, including similar medium- and short-wavelength cone photoreceptors and spatial distribution of rod photoreceptors.^[@B51],[@B52]^ Transgenic pigs expressing P347L mutation in the *RHO* gene created by pronuclear microinjection showed similar progressive cone photoreceptor degeneration and loss of function in cone-mediated vision as humans.^[@B53]^ Expression of the most common human P23H mutation in the rhodopsin gene was developed in a minipig model via SCNT and resulted in successful mirroring of the human phenotype of RP.^[@B54]^ Recently, Fernandez de Castro et al.^[@B55]^ created a pig model carrying P23H mutation that lacks rod function. Independent of the rod, the cone function developed normally for the first 30 days and then slowly declined. The same group has recently reported the effects of RHO^P23H^ expression on rod and cone photoreceptor in pig embryos. This resulted in an abnormal morphological and functional development of rod photoreceptors, but no change in cone photoreceptors was observed related to the cone dysfunction.^[@B56]^ Therefore, this large animal model may be useful in the therapeutic intervention to rescue cone function in RP patients.

A pig model for a cone--rod dystrophy (CORD) characterized by the progressive loss of cone cells was developed recently by using lentiviral transgenesis. It has been reported that guanylate cyclase 2D gene (*GUCY2D*) mutations are a frequent cause for autosomal dominant CORD.^[@B57],[@B58]^ The pigs expressing a *GUCY2D* mutation can be useful to understand the pathophysiology of the disease.^[@B59]^

Truncation mutations in the elongation of very long chain fatty acids protein 4 (*ELOVL4*) gene cause macular dystrophy. Photoreceptor topography in the pig retina is more similar to that in humans as it includes cone-rich, macula-like area centralis, whereas mice lack a macular. Transgenic pigs expressing disease-causing *ELOVL4* mutations were generated by pronuclear DNA injection and SCNT.^[@B60]^ A detailed analysis showed photoreceptor loss, disorganized inner and outer segments, and diminished electroretinography responses, suggesting that the transgenic pigs mirror macular degeneration and provide an unique model for therapeutic interventions.

Immunology {#s009}
----------

The first successful immunodeficient pig model was generated by homologous recombination in porcine fetal fibroblasts resulting in a interleukin-2 receptor subunit gamma (*IL2RG*) deletion.^[@B61]^ IL2RG is responsible for growth and maturation of T cells and NK cells via signaling through different interleukins.^[@B62]^ The resulting *IL2RG* heterozygous male pigs showed deficiency of T and NK cells, and lacked thymus, similar to human SCID, which is a genetic disorder characterized by malfunctioning of T- and B-lymphocytes.^[@B63]^ Watanabe et al.^[@B64]^ generated *IL2RG* knockout pigs by zinc-finger nuclease technology, which showed an identical phenotype with above-mentioned pig model.

Subsequently, SCID pig models were established by TALENs targeting *RAG1* and *RAG2* in porcine fetal fibroblasts, followed by SCNT. Bi-allelic mutant *RAG1/2* piglets showed the absence of mature B and T lymphocytes in their lymphoid organs, which was the result of the deficit in V(D)J recombination. Compared to wild type, heterozygous *RAG2* piglets showed similar development and sexual maturity, whereas the *RAG1* or *RAG2* homozygous piglets were characterized by a higher death rate.^[@B65]^ Another SCID pig model carrying *RAG2* bi-allelic mutations has been generated resulting in piglets that lacked B- and T-cells, but possessed NK-cells, providing an alternative to immunocompromised mice for the assessment of tumorigenicity.^[@B66]^ Since the immune reactions of pigs and humans are quite similar, the *RAG2* knockout pigs may help to understand the phenotype of human SCID patients and to evaluate the efficacy and safety of cell transplantations.^[@B66]^ However, long-term maintenance of severely immunodeficient pigs would require housing under pathogen-free conditions, which currently is not available in most experimental pig facilities.

Xenotransplantation {#s010}
-------------------

Xenotransplantation seems to be one option to close the growing gap between demand and availability of appropriate organs for human patients with acute or chronic organ failure.^[@B67]^ Genetic engineering of pigs allows to overcome immunological hurdles for xenotransplantation and to prevent transmission of porcine pathogens to human recipients.

A major obstacle to successful porcine-to-primate xenotransplantation is caused by hyperacute rejection resulting from preformed antibodies that recognize a galactose-α1,3-galactose (α-Gal) carbohydrate.^[@B68]^ The synthesis of α-Gal epitopes is catalyzed by the alpha 1,3 galactosyl transferase1 gene (*GGTA1*) found in all mammals except old world monkeys, apes, and humans.^[@B69]^ The production of *GGTA1* knockout animals significantly increased the survival of xenotransplants, maximal survival rates of up to 3--6 months have been achieved with porcine *GGTA1* knockout organs (kidney or heart) transplanted to baboons, and hyperacute rejections were greatly reduced in the grafts.^[@B70],[@B71]^ The hyperacute rejection can be further reduced by simultaneous expression of human complement regulatory proteins such as CD46, CD55, or CD59 combined with a *GGTA1* deletion. A more advanced pig line carrying deletions of two xenoantigens, α-Gal and N-glycolylneuraminic acid, has been produced, and showed reduced humoral activity compared to a *GGTA1* knockout alone.^[@B72]^ In addition to the immunosuppressive approach, graft survival is considered to depend on coagulation dysregulation, leading to the development of thrombotic microangiopathy of the graft, consumptive coagulopathy of the recipient, or both.^[@B73]^

Recently, Bongoni et al.^[@B74]^ generated *GGTA1* heterozygous knockout/*hC46/HLA-E* transgenic pigs to explore the effect of hCD46/HLA-E expression on complement deposition, endothelial activation, and NK cell interaction. *Ex vivo* xenoperfusion of the transgenic pig limbs with human blood resulted in reduction of accumulation of C3b/c, C4b/c, and C6 and a reduced up-regulation of the proinflammatory cell adhesion molecules E-selectin and VCAM-1.^[@B74]^ Although the contribution of the HLA-E expression was not specified due to the double mutation, *hCD46*-expressing transgenic pigs lacking the α-Gal epitope resulted in reduced complement activation during *ex vivo* lung perfusions.^[@B75]^ Accordingly, these models will likely represent useful tools to develop strategy for xenotransplantation. A recent study describing the xenotransplantation of multitransgenic porcine islets into diabetic cynomolgus monkeys, however, did not demonstrate long-term correction of insulin and blood glucose levels.^[@B76]^

Extensive research has been conducted to reduce the potential risk of zoonotic pathogen transmission to human patients of a xenotransplantation; a particular emphasis has been put on porcine endogenous retrovirus (PERV).^[@B77],[@B78]^ RNA interference (RNAi) is a promising method for knocking down the PERV expression. The efficacy of RNAi to reduce PERV expression has been demonstrated in cloned piglets by targeting the *PERV* genes encoding capsid protein, reverse transcriptase, and envelope glycoprotein.^[@B79]^ It seems likely that these improvements will be helpful to increase the biosecurity of potential porcine xenotransplants. However, recent data suggest that other common opportunistic pathogens, like cytomegalovirus (CMV), influence xenograft survival in nonhuman primates and need to be controlled in a xenotransplantation scenario.^[@B83],[@B84]^

Conclusions and Perspectives {#s011}
============================

Rapidly increasing numbers of biomedical pig models were published in recent years ([Table 1](#T1){ref-type="table"}). The development of advanced methods for genetic engineering provided the basis for this recent movement. Advanced methodological improvements include the establishment of hyperactive transposases, recombinases, and programmable endonucleases. Together with more accurate genome data, precise genetic modifications became feasible. In own experiments, we explored and established the *SB* transposon system for porcine transgenesis. The *in ovo* transposition turned out to be a highly efficient method resulting in success rates of up to 60% transgenic piglets per litter.^[@B85],[@B86]^ Importantly, the monomeric *SB* transposons seem to escape epigenetic regulation, and faithful promoter-dependent expression patterns were obtained ([Fig. 2](#f2){ref-type="fig"}). Using the chimeric CAGGS promoter, an ubiquitous expression in somatic and germline cells was found.^[@B85],[@B87],[@B88]^ Induced PS cells derived from these animals showed a robust expression of the reporter ([Fig. 2](#f2){ref-type="fig"}) and will be instrumental for vital cell tracking studies, for example, to determine the fate of iPS cells in blastocyst complementation, to analyze the contribution to chimera formation, and to assess fetal cell chimerism in the pig.^[@B89]^ The robust reporter expression will also allow to track transplanted cells in pig models of innovative cell therapies. In combination with a recombinase, such as the Cre/loxP system, the *SB*-transposon-tagged genomic loci can be readdressed, thereby enabling targeted integration of functional transgenes into pretested genomic loci ([Fig. 3](#f3){ref-type="fig"}).

![Fluorescent reporter transposon pigs as tool for vital cell tracking. **(A)** Schematic depiction of *Sleeping Beauty* (*SB*)--Venus transposon.^[@B85]^ **(B)** Transposon transgenic pigs, generated by cytoplasmic injection of plasmids, carrying a Venus reporter fluorescent green under specific excitation. Wild-type animals (front) appear bluish due to reflected and scattered excitation light.^[@B87]^ **(C)** Amazingly, the Venus reporter is also deposited in the hair, and two samples from transgenic (left and middle) and a hair sample from a wild-type pig (right) are shown under epifluorescence. **(D)** Same view as in **(C)** showing under darkfield conditions. Scale bar=1 cm. **(E)** Spermatozoa from a reporter transposon boar shown under differential interference contrast (DIC) and **(F)** as overlay of specific fluorescence and DIC images. The spermatozoa loaded with the Venus protein and allow tracking the fate of paternal proteins after fertilization.^[@B87]^ Scale bar=5 μm. **(G)** Porcine induced pluripotent stem cell colonies derived from an SB--Venus animal shown under Venus fluorescence conditions, and **(H)** brightfield view.](fig-2){#f2}

![Genetic engineering of the pig genome. **(A)** Additive genome engineering by transposase-catalyzed integration. Subsequently, a targeted replacement of the reporter against a transgene of choice is possible via Cre recombinase-mediated cassette exchange (RMCE).^[@B4],[@B85]^ **(B)** Subtractive genome engineering by a programmable nuclease approach. A designer nuclease, ZFN, TALEN, or CRISPR/Cas9, is directed against a protein-coding exon. The CRISPR/Cas9 system seems to combine the efficiency of ZFNs and TALENs with a much simpler design principle, as target-site selection is determined solely by base complementarity to the guide RNA. Indel formation after faulty repair will likely result in a frameshift mutation and a functional gene knockout. In principle, this mechanism can be coupled with homologous recombination.](fig-3){#f3}

The development of programmable endonucleases, like ZFNs, TALENs, and CRISPR/Cas nucleases, will complement this toolbox for genetic engineering of the pig ([Fig. 3](#f3){ref-type="fig"}).^[@B13],[@B14],[@B34],[@B90]^ It is anticipated that authentic pluripotent cells of the pig will be generated in the near future. Thus, genetic engineering in the pig will become a routine tool for the generation of relevant humanized pig models. The most obvious application of transgenic pigs will be for disease models and biomedical therapies, which are not well reflected in small rodent models. The expected progress for pig transgenesis (increase of success rates and decreasing costs) will make the pig an attractive complementary model for advanced approaches in biomedical and pharmaceutical research.

Pig models allow longitudinal studies of disease initiation and progression, thus allowing for improved diagnosis methods. The ongoing breeding of miniature pig strains, such as Göttingen, NIH and Sinclair minipigs, and the even smaller microminipigs,^[@B93]^ will contribute to a broader acceptance of this animal model. Miniaturized pigs will be easier to implement in existing infrastructures and will fit in current schedules for pharmacological testing of potential drug substance.

Genetically modified pigs will complement and extend disease modeling in transgenic mice, in particular for diseases with slowly progressing pathophysiology. The examples of biomedical pig models discussed here demonstrate that the technology for genetic engineering in this species caught up to the possibilities already available in the mouse. In the near future, the biomedical and pharmaceutical research with genetically engineered pigs will have a significant impact for molecular and cellular understanding of disease development, early diagnosis, and therapeutic interventions, and will establish the "laboratory pig" as valuable large mammalian model species. Moreover, pig models will allow the preclinical assessment of novel cell therapies to restore diseased tissues and organs, and to test the prospects of genetic correction of mutated alleles.
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AAV

:   adeno-associated virus

Aβ

:   amyloid β peptide

AD

:   Alzheimer\'s disease

APC

:   adenomatous polyposis coli (gene)

APP

:   amyloid precursor protein

BRCA

:   breast cancer (gene)

C3, C4, C6

:   complement components

CAGGS

:   CMV enhancer, chicken beta-actin promoter

CD46, CD55, CD59

:   complement proteins

CF

:   cystic fibrosis

CFTR

:   cystic fibrosis transmembrane regulator

CMV

:   cytomegalovirus

CORD

:   cone--rod dystrophy

Cre

:   causes recombination

CRISPR

:   clustered regularly interspaced short palindromic repeats

DIC

:   differential interference contrast

DM

:   diabetes mellitus

eNOS

:   endothelial nitric oxide synthase

ELOV4

:   elongation of very long chain fatty acids protein 4

ES

:   embryonic stem (cell)

FAD2

:   fatty acid desaturase 2 (gene)

FAP

:   familiar adenomatous polyposis

GGTA1

:   alpha 1,3 galactosyltransferase 1

GIP

:   glucose-dependent insulinotropic polypeptide

GUCY2D

:   guanylate cyclase 2D (gene)

HD

:   Huntington\'s disease

HLA-E

:   class I histocompatibility antigen, alpha chain E

HNF-1α

:   hepatocyte nuclear factor 1α

HTT

:   huntingtin (gene)

IL2RG

:   interleukin-2 receptor subunit gamma

Indel

:   insertion of deletion of bases

INS

:   insulin

iPS

:   induced pluripotent stem (cell)

ITR

:   inverted terminal repeats

LDL

:   low-density lipoprotein

MSC

:   mesenchymal stem cell

NK cell

:   natural killer cell

NO

:   nitric oxide

PCSK9

:   protein convertase subtilisin/kexin type 9 (gene)

PERV

:   porcine endogenous retrovirus

PNI

:   pronuclear DNA injection

PPAR-γ

:   peroxisome proliferator-activated receptor-γ

PSEN

:   presenilin

RAG

:   recombination activating gene

RHO

:   rhodopsin

RMCE

:   recombinase mediated cassette exchange

RNAi

:   RNA interference

RP

:   retinitis pigmentosa

SB

:   Sleeping Beauty (transposon)

SCID

:   severe combined immunodeficiency

SCNT

:   somatic cell nuclear transfer

SORT

:   spontaneous object recognition test

TALEN

:   transactivator-like element nuclease

TP35

:   tumor protein 53

VCAM1

:   vascular cell adhesion molecule 1

Venus

:   variant of yellow fluorescent protein

ZFN

:   zinc finger nuclease
